tucatinib,trastuzumab
seagen
results: mountaineer phase 2 trial of her-2 #colorectalcancer fulfilled endpoint of 38% rr, pfs = 8.2m and median os of 24.1m #wcgic2022 #oncoalert #cancer #cancerresearch #clinicaltrial 
Co-Director GI Oncology/Co-Leader GI Research; Director, Young Adult Cancers Program; Co-Chair, NCI GI Steering Committee. ?? running/food  #AAPI